Alnylam and BridgeBio are competing for people who are switching from Pfizer’s blockbuster ATTR amyloidosis drug tafamidis while all three companies are fighting for new patients.

You may unsubscribe at any time. By signing up, you agree to our terms of use and privacy policy. This site is protected by reCAPTCHA and the Google privacy policy and terms of service apply.

Gene therapy developer CRISPR Therapeutics AG (CRSP) is navigating some regulatory and commercial dynamics. Its flagship gene ...

Despite his criticisms, Trump ultimately opted against removing Powell and thus avoided any legal fights that could ensue.

In 2025, the European Central Bank and its American counterpart have taken starkly different approaches to monetary policy, with the ECB continuing to slash interest rates, and the Fed holding them ...

Fintel reports that on April 17, 2025, BMO Capital upgraded their outlook for Trex (NYSE:TREX) from Market Perform to ...

Google illegally acted to preserve “monopoly power” in the ad-tech business, a federal judge ruled Thursday. It’s the second ...

BMO Capital lowered the firm’s price target on CSX (CSX) to $35 from $36 but keeps an Outperform rating on the shares. The company’s Q1 ...

Fintel reports that on April 17, 2025, BMO Capital downgraded their outlook for Novo Nordisk A (NYSE:NVO) from Outperform to ...

Tariff-driven volatility has redefined what's considered a "normal" day of bond-market trading, with traders contemplating "a wider scope of conceivable outcomes" as the global trade war unfolds, said ...

Pfizer said on Monday it has discontinued development of experimental weight-loss pill danuglipron after a trial patient ...

The U.S. economy defied worries of recession for the past three years and experienced surprisingly stellar growth. But don't expect a repeat in 2025: Weak or worse are the are only two paths for the ...